Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15553588 | 0.81 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL20921679 | 0.79 | RIPK1 (0.30) | RIPK1 | |
| SCHEMBL24706040 | 0.78 | RIPK1 (0.32) | RIPK1 | |
| SCHEMBL12225486 | 0.78 | RIPK1 (0.32) | RIPK1 | |
| SCHEMBL10211245 | 0.76 | RIPK1 (0.34) | RIPK1 | |
| SCHEMBL11238127 | 0.76 | RIPK1 (0.34) | RIPK1 | |
| SCHEMBL12225485 | 0.76 | RIPK1 (0.31) | RIPK1 | |
| SCHEMBL24298351 | 0.76 | RIPK1 (0.34) | RIPK1 | |
| SCHEMBL18822648 | 0.76 | ALDH1A1 (0.38) | ALDH1A1RIPK1 | |
| SCHEMBL13732695 | 0.74 | CETP (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110213145-A1 | Compounds and Methods for Inhibiting the Interaction of BCL Proteins with Binding Partners | INFINITY DISCOVERY, INC. (US) | 2011-09-01 | — | — | US | disclosed |
| US-7928244-B2 | Isoxazolidine small molecules; cancer, hyperproliferation disorders; blocking antiapoptotic function | INFINITY DISCOVERY, INC. (US) | 2011-04-19 | — | — | US | disclosed |
| EP-2064192-A2 | COMPOUNDS AND METHODS FOR INHIBITING THE INTERACTION OF BCL PROTEINS WITH BINDING PARTNERS | Infinity Discovery, Inc. (US) | 2009-06-03 | — | — | EP | disclosed |
| WO-2008024337-A2 | COMPOUNDS AND METHODS FOR INHIBITING THE INTERACTION OF BCL PROTEINS WITH BINDING PARTNERS | INFINITY DISCOVERY, INC. (US) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110213145-A1 | Compounds and Methods for Inhibiting the Interaction of BCL Proteins with Binding Partners | BCL2, BCL2L1, BCL2L11 | ALDH1A1 4058/4885RIPK1 348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.